Global Weight Loss Therapeutics
Global Weight Loss Therapeutics

Weight Loss Therapeutics Comprehensive Study by Therapy (Intensive Behavioural Therapy, Self-Monitoring Therapy), End Users (Hospitals, Therapy Clinics, Pharmaceuticals Organization), Distribution Channel (Online {Company Website, E-Commerce Website}, Offline {Retail Pharmacies, Distributor}), Product (Plenity, Orlistat, Lorcaserin, Green Tea Extract, Others) Players and Region - Global Market Outlook to 2026

Weight Loss Therapeutics Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Sep 2021 Edition 204 Pages 211 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Industry Background:
Weight loss therapy is a type of cognitive-behavioral therapy that emphasizes weight loss through lifestyle changes. The physical aspect of losing weight is affected by diet and exercise. The mental side of things is addressed in therapy. Being overweight increases the risk of not only medical/physical disorders, but also mental health issues. People who are overweight are more likely to suffer from low self-esteem, anxiety, and depression. Obesity clearly has a negative impact on a person's life, and finding a non-traditional strategy to weight loss may be the key to success. Weight loss therapy may not be able to help people lose weight on its own, but it can help them get more out of diet and exercise.This growth is primarily driven by Increased Awareness Regarding Fitness and Personal Health and Rise in Number of Diabetic Patients across the World.

Globally, a noticeable market trend is evident New Diet Trends for Weight Loss Therapy Include Plant-Based Flexitarian Diet, Ketogenic Diet, Mediterranean Diet. Major Players, such as Herbalife (United States), Medifast (United States), Lululemon Athletica (Canada), Arena Pharmaceuticals (Switzerland), Novartis (Switzerland), Life Time Fitness (United States), Vivus (United States), Sanofi (France), Biocon Ltd (India) and Novo Nordisk (Denmark) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

In June 2021 Novo Nordisk released a statement stating that its New Product Wegovy received FDA Approval. Wegovy injectable 2.4 mg is the first and only once-weekly prescription weight-loss drug. Adults with obesity (BMI 30) or overweight (overweight) (BMI 27) who also have weight-related medical concerns can use Wegovy in conjunction with a reduced-calorie diet plan and increased physical exercise to help them lose weight and keep it off.

Market Drivers
  • Increased Awareness Regarding Fitness and Personal Health
  • Rise in Number of Diabetic Patients across the World

Market Trend
  • New Diet Trends for Weight Loss Therapy Include Plant-Based Flexitarian Diet, Ketogenic Diet, Mediterranean Diet

Restraints
  • Excess Usage of Weight Loss Pills can have Serious Side Effects

Opportunities
Unhealthy Lifestyle Such as Eating Junk Food, irregular Sleeping Pattern
Challenges
High Cost of Weight Loss Therapy and Diets and The Effectiveness of Currently Available Medicines is Limited

AMA Research follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts, but also include significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Weight Loss Therapeutics Study Sheds Light on
— The Weight Loss Therapeutics Market status quo and key characteristics. To end this, Analyst at AMA organize and took survey of the Weight Loss Therapeutics industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Weight Loss Therapeutics industry is heading and what are the top priorities. Insights are drawn from financial analysis, the survey and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold value they currently claim, or capture the new addressable opportunity.

Frequently Asked Questions (FAQ):

1. What are the years considered in the Weight Loss Therapeutics Market?
Historical year: 2016-2020; Base year: 2020; Forecast period: 2021 to 2026

2. Who are the key players profiled in the Weight Loss Therapeutics Market?
Companies that are profiled in Global Weight Loss Therapeutics Market are Herbalife (United States), Medifast (United States), Lululemon Athletica (Canada), Arena Pharmaceuticals (Switzerland), Novartis (Switzerland), Life Time Fitness (United States), Vivus (United States), Sanofi (France), Biocon Ltd (India) and Novo Nordisk (Denmark) etc.

3. What is Weight Loss Therapeutics Market?
Weight loss therapy is a type of cognitive-behavioral therapy that emphasizes weight loss through lifestyle changes. The physical aspect of losing weight is affected by diet and exercise. The mental side of things is addressed in therapy. Being overweight increases the risk of not only medical/physical disorders, but also mental health issues. People who are overweight are more likely to suffer from low self-esteem, anxiety, and depression. Obesity clearly has a negative impact on a person's life, and finding a non-traditional strategy to weight loss may be the key to success. Weight loss therapy may not be able to help people lose weight on its own, but it can help them get more out of diet and exercise.
Report Objectives / Segmentation Covered
By Therapy
  • Intensive Behavioural Therapy
  • Self-Monitoring Therapy

By End Users
  • Hospitals
  • Therapy Clinics
  • Pharmaceuticals Organization

By Distribution Channel
  • Online {Company Website, E-Commerce Website}
  • Offline {Retail Pharmacies, Distributor}

By Product
  • Plenity
  • Orlistat
  • Lorcaserin
  • Green Tea Extract
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Awareness Regarding Fitness and Personal Health
      • 3.2.2. Rise in Number of Diabetic Patients across the World
    • 3.3. Market Challenges
      • 3.3.1. High Cost of Weight Loss Therapy and Diets
      • 3.3.2. The Effectiveness of Currently Available Medicines is Limited
    • 3.4. Market Trends
      • 3.4.1. New Diet Trends for Weight Loss Therapy Include Plant-Based Flexitarian Diet, Ketogenic Diet, Mediterranean Diet
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Weight Loss Therapeutics, by Therapy, End Users, Distribution Channel, Product and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Weight Loss Therapeutics (Value)
      • 5.2.1. Global Weight Loss Therapeutics by: Therapy (Value)
        • 5.2.1.1. Intensive Behavioural Therapy
        • 5.2.1.2. Self-Monitoring Therapy
      • 5.2.2. Global Weight Loss Therapeutics by: End Users (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Therapy Clinics
        • 5.2.2.3. Pharmaceuticals Organization
      • 5.2.3. Global Weight Loss Therapeutics by: Distribution Channel (Value)
        • 5.2.3.1. Online {Company Website, E-Commerce Website}
        • 5.2.3.2. Offline {Retail Pharmacies, Distributor}
      • 5.2.4. Global Weight Loss Therapeutics by: Product (Value)
        • 5.2.4.1. Plenity
        • 5.2.4.2. Orlistat
        • 5.2.4.3. Lorcaserin
        • 5.2.4.4. Green Tea Extract
        • 5.2.4.5. Others
      • 5.2.5. Global Weight Loss Therapeutics Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Weight Loss Therapeutics (Price)
  • 6. Weight Loss Therapeutics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Herbalife (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Medifast (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Lululemon Athletica (Canada)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Arena Pharmaceuticals (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Novartis (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Life Time Fitness (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Vivus (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Sanofi (France)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Biocon Ltd (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Novo Nordisk (Denmark)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Weight Loss Therapeutics Sale, by Therapy, End Users, Distribution Channel, Product and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Weight Loss Therapeutics (Value)
      • 7.2.1. Global Weight Loss Therapeutics by: Therapy (Value)
        • 7.2.1.1. Intensive Behavioural Therapy
        • 7.2.1.2. Self-Monitoring Therapy
      • 7.2.2. Global Weight Loss Therapeutics by: End Users (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Therapy Clinics
        • 7.2.2.3. Pharmaceuticals Organization
      • 7.2.3. Global Weight Loss Therapeutics by: Distribution Channel (Value)
        • 7.2.3.1. Online {Company Website, E-Commerce Website}
        • 7.2.3.2. Offline {Retail Pharmacies, Distributor}
      • 7.2.4. Global Weight Loss Therapeutics by: Product (Value)
        • 7.2.4.1. Plenity
        • 7.2.4.2. Orlistat
        • 7.2.4.3. Lorcaserin
        • 7.2.4.4. Green Tea Extract
        • 7.2.4.5. Others
      • 7.2.5. Global Weight Loss Therapeutics Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Weight Loss Therapeutics (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Weight Loss Therapeutics: by Therapy(USD Million)
  • Table 2. Weight Loss Therapeutics Intensive Behavioural Therapy , by Region USD Million (2015-2020)
  • Table 3. Weight Loss Therapeutics Self-Monitoring Therapy , by Region USD Million (2015-2020)
  • Table 4. Weight Loss Therapeutics: by End Users(USD Million)
  • Table 5. Weight Loss Therapeutics Hospitals , by Region USD Million (2015-2020)
  • Table 6. Weight Loss Therapeutics Therapy Clinics , by Region USD Million (2015-2020)
  • Table 7. Weight Loss Therapeutics Pharmaceuticals Organization , by Region USD Million (2015-2020)
  • Table 8. Weight Loss Therapeutics: by Distribution Channel(USD Million)
  • Table 9. Weight Loss Therapeutics Online {Company Website, E-Commerce Website} , by Region USD Million (2015-2020)
  • Table 10. Weight Loss Therapeutics Offline {Retail Pharmacies, Distributor} , by Region USD Million (2015-2020)
  • Table 11. Weight Loss Therapeutics: by Product(USD Million)
  • Table 12. Weight Loss Therapeutics Plenity , by Region USD Million (2015-2020)
  • Table 13. Weight Loss Therapeutics Orlistat , by Region USD Million (2015-2020)
  • Table 14. Weight Loss Therapeutics Lorcaserin , by Region USD Million (2015-2020)
  • Table 15. Weight Loss Therapeutics Green Tea Extract , by Region USD Million (2015-2020)
  • Table 16. Weight Loss Therapeutics Others , by Region USD Million (2015-2020)
  • Table 17. South America Weight Loss Therapeutics, by Country USD Million (2015-2020)
  • Table 18. South America Weight Loss Therapeutics, by Therapy USD Million (2015-2020)
  • Table 19. South America Weight Loss Therapeutics, by End Users USD Million (2015-2020)
  • Table 20. South America Weight Loss Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 21. South America Weight Loss Therapeutics, by Product USD Million (2015-2020)
  • Table 22. Brazil Weight Loss Therapeutics, by Therapy USD Million (2015-2020)
  • Table 23. Brazil Weight Loss Therapeutics, by End Users USD Million (2015-2020)
  • Table 24. Brazil Weight Loss Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 25. Brazil Weight Loss Therapeutics, by Product USD Million (2015-2020)
  • Table 26. Argentina Weight Loss Therapeutics, by Therapy USD Million (2015-2020)
  • Table 27. Argentina Weight Loss Therapeutics, by End Users USD Million (2015-2020)
  • Table 28. Argentina Weight Loss Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 29. Argentina Weight Loss Therapeutics, by Product USD Million (2015-2020)
  • Table 30. Rest of South America Weight Loss Therapeutics, by Therapy USD Million (2015-2020)
  • Table 31. Rest of South America Weight Loss Therapeutics, by End Users USD Million (2015-2020)
  • Table 32. Rest of South America Weight Loss Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 33. Rest of South America Weight Loss Therapeutics, by Product USD Million (2015-2020)
  • Table 34. Asia Pacific Weight Loss Therapeutics, by Country USD Million (2015-2020)
  • Table 35. Asia Pacific Weight Loss Therapeutics, by Therapy USD Million (2015-2020)
  • Table 36. Asia Pacific Weight Loss Therapeutics, by End Users USD Million (2015-2020)
  • Table 37. Asia Pacific Weight Loss Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 38. Asia Pacific Weight Loss Therapeutics, by Product USD Million (2015-2020)
  • Table 39. China Weight Loss Therapeutics, by Therapy USD Million (2015-2020)
  • Table 40. China Weight Loss Therapeutics, by End Users USD Million (2015-2020)
  • Table 41. China Weight Loss Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 42. China Weight Loss Therapeutics, by Product USD Million (2015-2020)
  • Table 43. Japan Weight Loss Therapeutics, by Therapy USD Million (2015-2020)
  • Table 44. Japan Weight Loss Therapeutics, by End Users USD Million (2015-2020)
  • Table 45. Japan Weight Loss Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 46. Japan Weight Loss Therapeutics, by Product USD Million (2015-2020)
  • Table 47. India Weight Loss Therapeutics, by Therapy USD Million (2015-2020)
  • Table 48. India Weight Loss Therapeutics, by End Users USD Million (2015-2020)
  • Table 49. India Weight Loss Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 50. India Weight Loss Therapeutics, by Product USD Million (2015-2020)
  • Table 51. South Korea Weight Loss Therapeutics, by Therapy USD Million (2015-2020)
  • Table 52. South Korea Weight Loss Therapeutics, by End Users USD Million (2015-2020)
  • Table 53. South Korea Weight Loss Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 54. South Korea Weight Loss Therapeutics, by Product USD Million (2015-2020)
  • Table 55. Taiwan Weight Loss Therapeutics, by Therapy USD Million (2015-2020)
  • Table 56. Taiwan Weight Loss Therapeutics, by End Users USD Million (2015-2020)
  • Table 57. Taiwan Weight Loss Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 58. Taiwan Weight Loss Therapeutics, by Product USD Million (2015-2020)
  • Table 59. Australia Weight Loss Therapeutics, by Therapy USD Million (2015-2020)
  • Table 60. Australia Weight Loss Therapeutics, by End Users USD Million (2015-2020)
  • Table 61. Australia Weight Loss Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 62. Australia Weight Loss Therapeutics, by Product USD Million (2015-2020)
  • Table 63. Rest of Asia-Pacific Weight Loss Therapeutics, by Therapy USD Million (2015-2020)
  • Table 64. Rest of Asia-Pacific Weight Loss Therapeutics, by End Users USD Million (2015-2020)
  • Table 65. Rest of Asia-Pacific Weight Loss Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 66. Rest of Asia-Pacific Weight Loss Therapeutics, by Product USD Million (2015-2020)
  • Table 67. Europe Weight Loss Therapeutics, by Country USD Million (2015-2020)
  • Table 68. Europe Weight Loss Therapeutics, by Therapy USD Million (2015-2020)
  • Table 69. Europe Weight Loss Therapeutics, by End Users USD Million (2015-2020)
  • Table 70. Europe Weight Loss Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 71. Europe Weight Loss Therapeutics, by Product USD Million (2015-2020)
  • Table 72. Germany Weight Loss Therapeutics, by Therapy USD Million (2015-2020)
  • Table 73. Germany Weight Loss Therapeutics, by End Users USD Million (2015-2020)
  • Table 74. Germany Weight Loss Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 75. Germany Weight Loss Therapeutics, by Product USD Million (2015-2020)
  • Table 76. France Weight Loss Therapeutics, by Therapy USD Million (2015-2020)
  • Table 77. France Weight Loss Therapeutics, by End Users USD Million (2015-2020)
  • Table 78. France Weight Loss Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 79. France Weight Loss Therapeutics, by Product USD Million (2015-2020)
  • Table 80. Italy Weight Loss Therapeutics, by Therapy USD Million (2015-2020)
  • Table 81. Italy Weight Loss Therapeutics, by End Users USD Million (2015-2020)
  • Table 82. Italy Weight Loss Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 83. Italy Weight Loss Therapeutics, by Product USD Million (2015-2020)
  • Table 84. United Kingdom Weight Loss Therapeutics, by Therapy USD Million (2015-2020)
  • Table 85. United Kingdom Weight Loss Therapeutics, by End Users USD Million (2015-2020)
  • Table 86. United Kingdom Weight Loss Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 87. United Kingdom Weight Loss Therapeutics, by Product USD Million (2015-2020)
  • Table 88. Netherlands Weight Loss Therapeutics, by Therapy USD Million (2015-2020)
  • Table 89. Netherlands Weight Loss Therapeutics, by End Users USD Million (2015-2020)
  • Table 90. Netherlands Weight Loss Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 91. Netherlands Weight Loss Therapeutics, by Product USD Million (2015-2020)
  • Table 92. Rest of Europe Weight Loss Therapeutics, by Therapy USD Million (2015-2020)
  • Table 93. Rest of Europe Weight Loss Therapeutics, by End Users USD Million (2015-2020)
  • Table 94. Rest of Europe Weight Loss Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 95. Rest of Europe Weight Loss Therapeutics, by Product USD Million (2015-2020)
  • Table 96. MEA Weight Loss Therapeutics, by Country USD Million (2015-2020)
  • Table 97. MEA Weight Loss Therapeutics, by Therapy USD Million (2015-2020)
  • Table 98. MEA Weight Loss Therapeutics, by End Users USD Million (2015-2020)
  • Table 99. MEA Weight Loss Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 100. MEA Weight Loss Therapeutics, by Product USD Million (2015-2020)
  • Table 101. Middle East Weight Loss Therapeutics, by Therapy USD Million (2015-2020)
  • Table 102. Middle East Weight Loss Therapeutics, by End Users USD Million (2015-2020)
  • Table 103. Middle East Weight Loss Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 104. Middle East Weight Loss Therapeutics, by Product USD Million (2015-2020)
  • Table 105. Africa Weight Loss Therapeutics, by Therapy USD Million (2015-2020)
  • Table 106. Africa Weight Loss Therapeutics, by End Users USD Million (2015-2020)
  • Table 107. Africa Weight Loss Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 108. Africa Weight Loss Therapeutics, by Product USD Million (2015-2020)
  • Table 109. North America Weight Loss Therapeutics, by Country USD Million (2015-2020)
  • Table 110. North America Weight Loss Therapeutics, by Therapy USD Million (2015-2020)
  • Table 111. North America Weight Loss Therapeutics, by End Users USD Million (2015-2020)
  • Table 112. North America Weight Loss Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 113. North America Weight Loss Therapeutics, by Product USD Million (2015-2020)
  • Table 114. United States Weight Loss Therapeutics, by Therapy USD Million (2015-2020)
  • Table 115. United States Weight Loss Therapeutics, by End Users USD Million (2015-2020)
  • Table 116. United States Weight Loss Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 117. United States Weight Loss Therapeutics, by Product USD Million (2015-2020)
  • Table 118. Canada Weight Loss Therapeutics, by Therapy USD Million (2015-2020)
  • Table 119. Canada Weight Loss Therapeutics, by End Users USD Million (2015-2020)
  • Table 120. Canada Weight Loss Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 121. Canada Weight Loss Therapeutics, by Product USD Million (2015-2020)
  • Table 122. Mexico Weight Loss Therapeutics, by Therapy USD Million (2015-2020)
  • Table 123. Mexico Weight Loss Therapeutics, by End Users USD Million (2015-2020)
  • Table 124. Mexico Weight Loss Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 125. Mexico Weight Loss Therapeutics, by Product USD Million (2015-2020)
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Weight Loss Therapeutics: by Therapy(USD Million)
  • Table 137. Weight Loss Therapeutics Intensive Behavioural Therapy , by Region USD Million (2021-2026)
  • Table 138. Weight Loss Therapeutics Self-Monitoring Therapy , by Region USD Million (2021-2026)
  • Table 139. Weight Loss Therapeutics: by End Users(USD Million)
  • Table 140. Weight Loss Therapeutics Hospitals , by Region USD Million (2021-2026)
  • Table 141. Weight Loss Therapeutics Therapy Clinics , by Region USD Million (2021-2026)
  • Table 142. Weight Loss Therapeutics Pharmaceuticals Organization , by Region USD Million (2021-2026)
  • Table 143. Weight Loss Therapeutics: by Distribution Channel(USD Million)
  • Table 144. Weight Loss Therapeutics Online {Company Website, E-Commerce Website} , by Region USD Million (2021-2026)
  • Table 145. Weight Loss Therapeutics Offline {Retail Pharmacies, Distributor} , by Region USD Million (2021-2026)
  • Table 146. Weight Loss Therapeutics: by Product(USD Million)
  • Table 147. Weight Loss Therapeutics Plenity , by Region USD Million (2021-2026)
  • Table 148. Weight Loss Therapeutics Orlistat , by Region USD Million (2021-2026)
  • Table 149. Weight Loss Therapeutics Lorcaserin , by Region USD Million (2021-2026)
  • Table 150. Weight Loss Therapeutics Green Tea Extract , by Region USD Million (2021-2026)
  • Table 151. Weight Loss Therapeutics Others , by Region USD Million (2021-2026)
  • Table 152. South America Weight Loss Therapeutics, by Country USD Million (2021-2026)
  • Table 153. South America Weight Loss Therapeutics, by Therapy USD Million (2021-2026)
  • Table 154. South America Weight Loss Therapeutics, by End Users USD Million (2021-2026)
  • Table 155. South America Weight Loss Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 156. South America Weight Loss Therapeutics, by Product USD Million (2021-2026)
  • Table 157. Brazil Weight Loss Therapeutics, by Therapy USD Million (2021-2026)
  • Table 158. Brazil Weight Loss Therapeutics, by End Users USD Million (2021-2026)
  • Table 159. Brazil Weight Loss Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 160. Brazil Weight Loss Therapeutics, by Product USD Million (2021-2026)
  • Table 161. Argentina Weight Loss Therapeutics, by Therapy USD Million (2021-2026)
  • Table 162. Argentina Weight Loss Therapeutics, by End Users USD Million (2021-2026)
  • Table 163. Argentina Weight Loss Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 164. Argentina Weight Loss Therapeutics, by Product USD Million (2021-2026)
  • Table 165. Rest of South America Weight Loss Therapeutics, by Therapy USD Million (2021-2026)
  • Table 166. Rest of South America Weight Loss Therapeutics, by End Users USD Million (2021-2026)
  • Table 167. Rest of South America Weight Loss Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 168. Rest of South America Weight Loss Therapeutics, by Product USD Million (2021-2026)
  • Table 169. Asia Pacific Weight Loss Therapeutics, by Country USD Million (2021-2026)
  • Table 170. Asia Pacific Weight Loss Therapeutics, by Therapy USD Million (2021-2026)
  • Table 171. Asia Pacific Weight Loss Therapeutics, by End Users USD Million (2021-2026)
  • Table 172. Asia Pacific Weight Loss Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 173. Asia Pacific Weight Loss Therapeutics, by Product USD Million (2021-2026)
  • Table 174. China Weight Loss Therapeutics, by Therapy USD Million (2021-2026)
  • Table 175. China Weight Loss Therapeutics, by End Users USD Million (2021-2026)
  • Table 176. China Weight Loss Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 177. China Weight Loss Therapeutics, by Product USD Million (2021-2026)
  • Table 178. Japan Weight Loss Therapeutics, by Therapy USD Million (2021-2026)
  • Table 179. Japan Weight Loss Therapeutics, by End Users USD Million (2021-2026)
  • Table 180. Japan Weight Loss Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 181. Japan Weight Loss Therapeutics, by Product USD Million (2021-2026)
  • Table 182. India Weight Loss Therapeutics, by Therapy USD Million (2021-2026)
  • Table 183. India Weight Loss Therapeutics, by End Users USD Million (2021-2026)
  • Table 184. India Weight Loss Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 185. India Weight Loss Therapeutics, by Product USD Million (2021-2026)
  • Table 186. South Korea Weight Loss Therapeutics, by Therapy USD Million (2021-2026)
  • Table 187. South Korea Weight Loss Therapeutics, by End Users USD Million (2021-2026)
  • Table 188. South Korea Weight Loss Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 189. South Korea Weight Loss Therapeutics, by Product USD Million (2021-2026)
  • Table 190. Taiwan Weight Loss Therapeutics, by Therapy USD Million (2021-2026)
  • Table 191. Taiwan Weight Loss Therapeutics, by End Users USD Million (2021-2026)
  • Table 192. Taiwan Weight Loss Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 193. Taiwan Weight Loss Therapeutics, by Product USD Million (2021-2026)
  • Table 194. Australia Weight Loss Therapeutics, by Therapy USD Million (2021-2026)
  • Table 195. Australia Weight Loss Therapeutics, by End Users USD Million (2021-2026)
  • Table 196. Australia Weight Loss Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 197. Australia Weight Loss Therapeutics, by Product USD Million (2021-2026)
  • Table 198. Rest of Asia-Pacific Weight Loss Therapeutics, by Therapy USD Million (2021-2026)
  • Table 199. Rest of Asia-Pacific Weight Loss Therapeutics, by End Users USD Million (2021-2026)
  • Table 200. Rest of Asia-Pacific Weight Loss Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 201. Rest of Asia-Pacific Weight Loss Therapeutics, by Product USD Million (2021-2026)
  • Table 202. Europe Weight Loss Therapeutics, by Country USD Million (2021-2026)
  • Table 203. Europe Weight Loss Therapeutics, by Therapy USD Million (2021-2026)
  • Table 204. Europe Weight Loss Therapeutics, by End Users USD Million (2021-2026)
  • Table 205. Europe Weight Loss Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 206. Europe Weight Loss Therapeutics, by Product USD Million (2021-2026)
  • Table 207. Germany Weight Loss Therapeutics, by Therapy USD Million (2021-2026)
  • Table 208. Germany Weight Loss Therapeutics, by End Users USD Million (2021-2026)
  • Table 209. Germany Weight Loss Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 210. Germany Weight Loss Therapeutics, by Product USD Million (2021-2026)
  • Table 211. France Weight Loss Therapeutics, by Therapy USD Million (2021-2026)
  • Table 212. France Weight Loss Therapeutics, by End Users USD Million (2021-2026)
  • Table 213. France Weight Loss Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 214. France Weight Loss Therapeutics, by Product USD Million (2021-2026)
  • Table 215. Italy Weight Loss Therapeutics, by Therapy USD Million (2021-2026)
  • Table 216. Italy Weight Loss Therapeutics, by End Users USD Million (2021-2026)
  • Table 217. Italy Weight Loss Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 218. Italy Weight Loss Therapeutics, by Product USD Million (2021-2026)
  • Table 219. United Kingdom Weight Loss Therapeutics, by Therapy USD Million (2021-2026)
  • Table 220. United Kingdom Weight Loss Therapeutics, by End Users USD Million (2021-2026)
  • Table 221. United Kingdom Weight Loss Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 222. United Kingdom Weight Loss Therapeutics, by Product USD Million (2021-2026)
  • Table 223. Netherlands Weight Loss Therapeutics, by Therapy USD Million (2021-2026)
  • Table 224. Netherlands Weight Loss Therapeutics, by End Users USD Million (2021-2026)
  • Table 225. Netherlands Weight Loss Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 226. Netherlands Weight Loss Therapeutics, by Product USD Million (2021-2026)
  • Table 227. Rest of Europe Weight Loss Therapeutics, by Therapy USD Million (2021-2026)
  • Table 228. Rest of Europe Weight Loss Therapeutics, by End Users USD Million (2021-2026)
  • Table 229. Rest of Europe Weight Loss Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 230. Rest of Europe Weight Loss Therapeutics, by Product USD Million (2021-2026)
  • Table 231. MEA Weight Loss Therapeutics, by Country USD Million (2021-2026)
  • Table 232. MEA Weight Loss Therapeutics, by Therapy USD Million (2021-2026)
  • Table 233. MEA Weight Loss Therapeutics, by End Users USD Million (2021-2026)
  • Table 234. MEA Weight Loss Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 235. MEA Weight Loss Therapeutics, by Product USD Million (2021-2026)
  • Table 236. Middle East Weight Loss Therapeutics, by Therapy USD Million (2021-2026)
  • Table 237. Middle East Weight Loss Therapeutics, by End Users USD Million (2021-2026)
  • Table 238. Middle East Weight Loss Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 239. Middle East Weight Loss Therapeutics, by Product USD Million (2021-2026)
  • Table 240. Africa Weight Loss Therapeutics, by Therapy USD Million (2021-2026)
  • Table 241. Africa Weight Loss Therapeutics, by End Users USD Million (2021-2026)
  • Table 242. Africa Weight Loss Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 243. Africa Weight Loss Therapeutics, by Product USD Million (2021-2026)
  • Table 244. North America Weight Loss Therapeutics, by Country USD Million (2021-2026)
  • Table 245. North America Weight Loss Therapeutics, by Therapy USD Million (2021-2026)
  • Table 246. North America Weight Loss Therapeutics, by End Users USD Million (2021-2026)
  • Table 247. North America Weight Loss Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 248. North America Weight Loss Therapeutics, by Product USD Million (2021-2026)
  • Table 249. United States Weight Loss Therapeutics, by Therapy USD Million (2021-2026)
  • Table 250. United States Weight Loss Therapeutics, by End Users USD Million (2021-2026)
  • Table 251. United States Weight Loss Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 252. United States Weight Loss Therapeutics, by Product USD Million (2021-2026)
  • Table 253. Canada Weight Loss Therapeutics, by Therapy USD Million (2021-2026)
  • Table 254. Canada Weight Loss Therapeutics, by End Users USD Million (2021-2026)
  • Table 255. Canada Weight Loss Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 256. Canada Weight Loss Therapeutics, by Product USD Million (2021-2026)
  • Table 257. Mexico Weight Loss Therapeutics, by Therapy USD Million (2021-2026)
  • Table 258. Mexico Weight Loss Therapeutics, by End Users USD Million (2021-2026)
  • Table 259. Mexico Weight Loss Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 260. Mexico Weight Loss Therapeutics, by Product USD Million (2021-2026)
  • Table 261. Research Programs/Design for This Report
  • Table 262. Key Data Information from Secondary Sources
  • Table 263. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Weight Loss Therapeutics: by Therapy USD Million (2015-2020)
  • Figure 5. Global Weight Loss Therapeutics: by End Users USD Million (2015-2020)
  • Figure 6. Global Weight Loss Therapeutics: by Distribution Channel USD Million (2015-2020)
  • Figure 7. Global Weight Loss Therapeutics: by Product USD Million (2015-2020)
  • Figure 8. South America Weight Loss Therapeutics Share (%), by Country
  • Figure 9. Asia Pacific Weight Loss Therapeutics Share (%), by Country
  • Figure 10. Europe Weight Loss Therapeutics Share (%), by Country
  • Figure 11. MEA Weight Loss Therapeutics Share (%), by Country
  • Figure 12. North America Weight Loss Therapeutics Share (%), by Country
  • Figure 13. Global Weight Loss Therapeutics share by Players 2020 (%)
  • Figure 14. Global Weight Loss Therapeutics share by Players (Top 3) 2020(%)
  • Figure 15. Global Weight Loss Therapeutics share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Herbalife (United States) Revenue, Net Income and Gross profit
  • Figure 18. Herbalife (United States) Revenue: by Geography 2020
  • Figure 19. Medifast (United States) Revenue, Net Income and Gross profit
  • Figure 20. Medifast (United States) Revenue: by Geography 2020
  • Figure 21. Lululemon Athletica (Canada) Revenue, Net Income and Gross profit
  • Figure 22. Lululemon Athletica (Canada) Revenue: by Geography 2020
  • Figure 23. Arena Pharmaceuticals (Switzerland) Revenue, Net Income and Gross profit
  • Figure 24. Arena Pharmaceuticals (Switzerland) Revenue: by Geography 2020
  • Figure 25. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 26. Novartis (Switzerland) Revenue: by Geography 2020
  • Figure 27. Life Time Fitness (United States) Revenue, Net Income and Gross profit
  • Figure 28. Life Time Fitness (United States) Revenue: by Geography 2020
  • Figure 29. Vivus (United States) Revenue, Net Income and Gross profit
  • Figure 30. Vivus (United States) Revenue: by Geography 2020
  • Figure 31. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 32. Sanofi (France) Revenue: by Geography 2020
  • Figure 33. Biocon Ltd (India) Revenue, Net Income and Gross profit
  • Figure 34. Biocon Ltd (India) Revenue: by Geography 2020
  • Figure 35. Novo Nordisk (Denmark) Revenue, Net Income and Gross profit
  • Figure 36. Novo Nordisk (Denmark) Revenue: by Geography 2020
  • Figure 37. Global Weight Loss Therapeutics: by Therapy USD Million (2021-2026)
  • Figure 38. Global Weight Loss Therapeutics: by End Users USD Million (2021-2026)
  • Figure 39. Global Weight Loss Therapeutics: by Distribution Channel USD Million (2021-2026)
  • Figure 40. Global Weight Loss Therapeutics: by Product USD Million (2021-2026)
  • Figure 41. South America Weight Loss Therapeutics Share (%), by Country
  • Figure 42. Asia Pacific Weight Loss Therapeutics Share (%), by Country
  • Figure 43. Europe Weight Loss Therapeutics Share (%), by Country
  • Figure 44. MEA Weight Loss Therapeutics Share (%), by Country
  • Figure 45. North America Weight Loss Therapeutics Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Herbalife (United States)
  • Medifast (United States)
  • Lululemon Athletica (Canada)
  • Arena Pharmaceuticals (Switzerland)
  • Novartis (Switzerland)
  • Life Time Fitness (United States)
  • Vivus (United States)
  • Sanofi (France)
  • Biocon Ltd (India)
  • Novo Nordisk (Denmark)
Additional players considered in the study are as follows:
Noom (Ukraine) , EnteroMedics (United States) , Oviva (United Kingdom)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation